Baird downgrades Array BioPharma (Nasdaq: ARRY) from Buy to Neutral. Price target $3.

Baird analyst says, "Despite some ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE